COCP Cocrystal Pharma, Inc. - 8-K

Item
7.01 Regulation FD Disclosure.

On
April 2, 2026, Cocrystal Pharma, Inc. (the “Company”) issued a press release, announcing that the U.S. Food and Drug Administration
(FDA) has granted Fast Track designation to the Company’s oral, direct acting protease inhibitor, CDI-988, the first oral antiviral
candidate being developed for treatment and prophylaxis of norovirus infection. A copy of the press release is furnished as Exhibit 99.1.

The
information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed
to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

Item
9.01 Financial Statements and Exhibits.

(d)
Exhibits

Exhibit

Description

99.1

Press Release dated April 2, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)